ribociclib + trastuzumab + letrozole

Ribociclib + trastuzumab + letrozole is an investigational chemotherapy-free combination regimen evaluated in the Phase 1b/2 MINI trial (NCT03913234). This triplet therapy combines three distinct mechanisms of action: **ribociclib** (a small molecule CDK4/6 inhibitor), **trastuzumab** (a HER2-targeting monoclonal antibody), and **letrozole** (a small molecule aromatase inhibitor). The regimen is designed to simultaneously target the cell cycle, HER2 signaling, and estrogen-driven pathways, which are often cross-linked in certain breast cancer subtypes. It is primarily indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) advanced or metastatic breast cancer. Clinical results from the MINI trial have demonstrated significant progression-free survival (PFS) and a manageable safety profile, positioning it as a potential first-line, chemotherapy-free treatment option for postmenopausal women with this specific breast cancer profile.

Brand names

KisqaliFemara

Other names

ribociclib plus trastuzumab plus letrozoleMINI regimen